Leronlimab
Monoclonal antibody against CCR5, for prevention of fusion of HIV with CCR5+ cells
Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of triple negative breast cancer and HIV infection.
Nº Q7120418 ★★
Peu commune · Savoirs
Leronlimab
Monoclonal antibody against CCR5, for prevention of fusion of HIV with CCR5+ cells
Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of triple negative breast cancer and HIV infection.
Dernier prix
—
Prix plancher
—
Médiane 7 j
—
Ventes 30 j
0
Fourchette 30 j
—
En circulation
0
Cours
médiane
min – max
ventes
Aucune vente sur la période
Voir le tableau
| Date | médiane | Min | Max | ventes |
|---|
Historique des ventes
- Dernière vente
- —
- Moyenne 30 j
- —
- Plus bas 30 j
- —
- Plus haut 30 j
- —
- Ventes 7 j
- 0
- Ventes 30 j
- 0
Aucune vente pour l'instant.
Ventes anonymes : ni acheteur ni vendeur. Les chiffres ne comptent que les ventes entre joueurs.
Sur Wikipédia
Texte en anglais Pas encore d'article dans ta langue : extrait en anglais.
Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of triple negative breast cancer and HIV infection. The United States Food and Drug Administration has designated PRO 140 for fast-track approval. It was investigated as a treatment for COVID-19 but found to be ineffective for that purpose.
Texte : Wikipédia en anglais, CC BY-SA 4.0. ·
